Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
53 hedge funds and large institutions have $428M invested in Inozyme Pharma in 2020 Q3 according to their latest regulatory filings, with 53 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
69.77% more ownership
Funds ownership: 0% → 69.77% (+70%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$63.8M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$60.7M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$50.4M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$49.8M |
| 5 |
DM
Deerfield Management
New York
|
+$28.6M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of Montreal
Toronto,
Ontario, Canada
| $8K | +$9.31K | +375 | New |
|
52
Millennium Management
New York
| $1.06K | +$998K | +40,164 | New |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$248 | +10 | New |
|
INZY Hedge Fund Activity: Q3 2020 in Review
53 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q3 2020, worth a combined $428M.
Buyers outnumbered sellers: 53 funds opened new INZY positions and 0 closed out — a net gain of 53 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $63.8M.
- 53 institutional investors held Inozyme Pharma (INZY) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $428M of Inozyme Pharma stock for Q3 2020.
- 53 funds opened new Inozyme Pharma positions in Q3 2020 and 0 closed out, a net change of +53 holders.
- The largest Inozyme Pharma buyer in Q3 2020 was Novo Holdings A/S, an estimated $63.8M added.
Based on aggregated 13F filings for Q3 2020.